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Background: The SPIRIT V Registry provides an evaluation of the performance of the XIENCE V Everolimus Eluting Coronary Stent System (EES) in 
real-world-use, including a complex, global patient population of multiple ethnic groups and variable clinical practice routines.
Methods: Patients with de novo, native coronary artery lesions in which the artery morphology and disease was suitable to be treated with a 
maximum of 4 planned EES were included. Target lesions had a reference vessel diameter (RVD) between 2.5 mm and 4.0 mm and lesion length (LL) 
≤ 28 mm.
2700 patients were enrolled at 93 sites outside of the USA between November 2006 and November 2007. The population included 30% diabetics 
and 29% of patients with > 1 target lesion treated. Mean RVD and LL were 2.97 mm and 15.6 mm.
Results: All events were adjudicated according to Academic Research Consortium definitions by an independent Clinical Events Committee.
In the overall population, at 30 days the primary endpoint composite of all death, Myocardial Infarction (MI) and Target Vessel Revascularization 
(TVR) was 2.7%.. One year results in this overall population included stent thrombosis rate (0.7 % definite and probable), cardiac death (1.1%), TLR 
(1.8%); and the composite rate of Cardiac Death, MI and TLR (5.1%).
This endpoint was further analyzed with respect to the following sub-groups:
Diabetic (n=794), Multiple TL treatment (n=760), Smaller vessels <=2.75mm (n=1068), Longer lesions >20mm, (n=911), Bifurcation lesions 
(n=306).
The results at 1 year of this composite endpoint of cardiac death, MI and TLR were 5.7%, 7.2%, 5.9%, 5.8% and 6.6% respectively.
Conclusions: 1 year results in the overall study population and in the sub-groups confirmed the safety and efficacy of the EES in a complex, real 
world population.
Detailed results on complex lesion and patient sub-groups will be presented.
